Icon

Exjade - (125, 250, 500 mg Tablet For Suspension)

DEFERASIROX Novartis
125, 250, 500 mg Tablet For Suspension
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
More Than 5
More Than 5
Used to treat iron overload caused by blood transfusions in adults and children at least 2 years old
Yes
******* ** *** ***** ** **** **** ** *** ****** **** ******* '*** (***** *, ****), '*** (**** **, ****) *** *** ************ *********. ****** *** ***** ***** *******'* **** **, ***** ***** * **** ** ** **** ******* *** *** ************ *********. ******* ********** *** ******* **** **** ******* & ***** ***** *** ***** ** ********** *** *** *****. ******* ******** * ****** ********* ******** ** *** **, **** ***** **** ****** *** *** **** ***********. ** ****** ******* ** ****** * ****** ****** ***** *, **** *** ***** & *** *** ***** ******** ** ****** ***** ***** *, **** ** ****** '*** ** *** **** ****** ********** *** **** ****** ** ****** ****.
Exjade Patent 1 Patent 2
******* ******* *******
***** ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ *** **** **, **** ******* ******** ******** ** ***** **, ****
***** ** \ ** *** **, **** ******* **** ****** **** ********
  1. *** *, **** : ******* ******** ******** ***** *** **** ** **** ******* '*** (***** *, ****), '*** (**** **, ****)
  2. *** **, **** : ******** ***** * **** ******* ******* ** ******** ***** ** **.
  3. *** **, **** : ******** ***** * **** ******* ***** ** ******** ***** ** ******** ** ***** ***** **** ** **** ****** '*** (***** *, ****), '*** (**** **, ****).
  4. *** *, **** : ********** **** ******* *** ******* ***** *** ***** ** ********** *** *** *****.
  5. *** **, **** : ********** *** ********* **** ***** ***** *** ***** ** ********* *** *** *****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.